Drug Approval | August 16, 2022
Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
ELCYS is the only FDA-approved cysteine hydrochloride injection on the market for use as an additive to amino acid solutions
QIAstat-Dx Viral Vesicular Panel tests for six pathogens that produce similar symptoms
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
New deal strengthens Congenica’s presence in India
The product will be manufactured at Lupin’s facility in Goa, India.
Use of IVUS recommended in all phases of lower extremity arterial and venous revascularization procedures to guide clinical decisions
Xofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the US for children as young as five years of age
AstraZeneca has acquired all outstanding equity of TeneoTwo in exchange for an upfront payment of $100m.
Subscribe To Our Newsletter & Stay Updated
